Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TTP889

Other · developed by vTv Therapeutics

Phase 2 Most advanced trial (none active)
VTVT Developer
1 Registered trials

What is TTP889?

TTP889 is a drug studied in coagulation-related trials, with heart failure listed as a condition in the trial record.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Cardiovascular
Developer
vTv Therapeutics (VTVT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00909298 Phase 2 Coagulation Terminated VTVT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Coagulation

More from vTv Therapeutics

Follow VTVT, the company behind TTP889

See VTVT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VTVT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.